What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Tomohide Tamura mostly deals with Internal medicine, Lung cancer, Oncology, Surgery and Epidermal growth factor receptor.
In his study, Tolerability and Toxicity is strongly linked to Gastroenterology, which falls under the umbrella field of Internal medicine.
His Lung cancer study incorporates themes from Respiratory disease, Survival rate, Carboplatin, Hazard ratio and Performance status.
His research in Oncology intersects with topics in Progressive disease, Prospective cohort study, Pathology and Survival analysis.
His Surgery study combines topics in areas such as Crizotinib, Alectinib and Adverse effect.
As a part of the same scientific study, he usually deals with the Chemotherapy, concentrating on Randomized controlled trial and frequently concerns with Clinical trial.
His most cited work include:
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer (2655 citations)
- Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer (1055 citations)
- Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer (654 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Oncology, Lung cancer, Chemotherapy and Gastroenterology.
Internal medicine is closely attributed to Surgery in his study.
His Oncology research includes elements of Clinical endpoint and Docetaxel.
His Lung cancer research includes themes of Carboplatin and Survival rate.
His work deals with themes such as Regimen and Radiation therapy, which intersect with Chemotherapy.
His study on Gastroenterology also encompasses disciplines like
- Pharmacokinetics together with Tolerability and Adverse effect,
- Nausea which intersects with area such as Vomiting.
He most often published in these fields:
- Internal medicine (64.21%)
- Oncology (40.04%)
- Lung cancer (39.85%)
What were the highlights of his more recent work (between 2014-2021)?
- Internal medicine (64.21%)
- Oncology (40.04%)
- Lung cancer (39.85%)
In recent papers he was focusing on the following fields of study:
Tomohide Tamura spends much of his time researching Internal medicine, Oncology, Lung cancer, Chemotherapy and Adverse effect.
His Internal medicine research incorporates elements of Gastroenterology and Surgery.
Chemotherapy regimen, Interim analysis and Randomized controlled trial is closely connected to Hazard ratio in his research, which is encompassed under the umbrella topic of Oncology.
In his work, Egfr mutation and microRNA is strongly intertwined with Cancer research, which is a subfield of Lung cancer.
Particularly relevant to Cisplatin is his body of work in Chemotherapy.
As part of one scientific family, Tomohide Tamura deals mainly with the area of Adverse effect, narrowing it down to issues related to the Pharmacokinetics, and often Tolerability, Paclitaxel and Dexamethasone.
Between 2014 and 2021, his most popular works were:
- Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial (384 citations)
- Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer (156 citations)
- The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer (150 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
His scientific interests lie mostly in Internal medicine, Oncology, Lung cancer, Surgery and Chemotherapy.
Many of his studies on Internal medicine apply to Pharmacology as well.
His biological study spans a wide range of topics, including Cancer and Gefitinib.
His studies deal with areas such as Progressive disease, Phases of clinical research, Carboplatin, Clinical endpoint and Placebo as well as Oncology.
His Lung cancer research is multidisciplinary, relying on both Survival rate, Chemotherapy regimen, Docetaxel and Hazard ratio.
His Pharmacokinetics research is multidisciplinary, incorporating elements of Gastroenterology and Leukopenia.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
